All In MedTech

Device Trial Radar · NCT06469398

A Post Market Device Study for the Treatment of Acne

A Post Market Study of a Laser System for the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Actual

Start

Jul 21, 2022

Primary completion

Mar 31, 2025

Study completion Aug 18, 2025

Sponsor

Lead sponsor
Cutera Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 21, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 16 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of the Cutera laser system for the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Cutera Laser SystemDevice

    Subjects will receive up to 6 laser treatments

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects Who are RespondersTime frame: 12 weeks post final treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology of Boca

    Boca Raton, Florida

  • Schweiger Dermatology PC, Reseach Division

    Hackensack, New Jersey

  • Bellaire Dermatology Associates

    Bellaire, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.